Is Less More? Rethinking Salvage Therapy in Pediatric Hodgkin Lymphoma
Now, mounting evidence, including findings from three prospective clinical trials, reveal that nontransplant options are an effective second-line treatment for low-risk cHL patients—precluding the need for HDC/ASCT.
Bình luận